Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Atria Investments Inc

Atria Investments Inc trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 24.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,561 shares of the company's stock after selling 849 shares during the quarter. Atria Investments Inc's holdings in Medpace were worth $851,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Proficio Capital Partners LLC lifted its holdings in Medpace by 34,497.4% in the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after acquiring an additional 241,827 shares during the last quarter. Iron Triangle Partners LP acquired a new position in shares of Medpace in the 3rd quarter valued at $64,371,000. GW&K Investment Management LLC lifted its stake in shares of Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after purchasing an additional 133,379 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after purchasing an additional 109,886 shares during the last quarter. Finally, DF Dent & Co. Inc. lifted its stake in shares of Medpace by 189.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company's stock valued at $53,841,000 after purchasing an additional 105,659 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $381.44.

Remove Ads

Medpace Stock Performance

Shares of MEDP opened at $317.93 on Friday. The stock has a market capitalization of $9.69 billion, a PE ratio of 25.17, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The company's 50-day simple moving average is $340.57 and its 200-day simple moving average is $341.84.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.